| Source: |
| Type: |
| Power to enhance an anti cancer effect |
| 1595- | Cu, | The Multifaceted Roles of Copper in Cancer: A Trace Metal Element with Dysregulated Metabolism, but Also a Target or a Bullet for Therapy |
| - | Review, | Var, | NA |
| 1598- | Cu, | Targeting copper in cancer therapy: 'Copper That Cancer' |
| - | Review, | Var, | NA |
| 1597- | Cu, | Anticancer potency of copper(II) complexes of thiosemicarbazones |
| - | Review, | Var, | NA |
| 1596- | Cu, | CDT, | Unveiling the promising anticancer effect of copper-based compounds: a comprehensive review |
| - | Review, | Var, | NA |
| 6190- | Cuc, | Cucurbitacin B induces G2 arrest and apoptosis via a reactive oxygen species-dependent mechanism in human colon adenocarcinoma SW480 cells |
| - | in-vitro, | Colon, | SW480 |
| 4830- | CUR, | Curcumin and Its Derivatives Induce Apoptosis in Human Cancer Cells by Mobilizing and Redox Cycling Genomic Copper Ions |
| - | in-vitro, | Var, | NA |
| 4826- | CUR, | The Bright Side of Curcumin: A Narrative Review of Its Therapeutic Potential in Cancer Management |
| - | Review, | Var, | NA |
| 410- | CUR, | Nrf2 depletion enhanced curcumin therapy effect in gastric cancer by inducing the excessive accumulation of ROS |
| - | vitro+vivo, | GC, | AGS | - | vitro+vivo, | GC, | HGC27 |
| 135- | CUR, | Curcumin induces apoptosis and protective autophagy in castration-resistant prostate cancer cells through iron chelation |
| - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | PC3 |
| 143- | CUR, | Nonautophagic cytoplasmic vacuolation death induction in human PC-3M prostate cancer by curcumin through reactive oxygen species -mediated endoplasmic reticulum stress |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | PC3 |
| 117- | CUR, | Increased Intracellular Reactive Oxygen Species Mediates the Anti-Cancer Effects of WZ35 via Activating Mitochondrial Apoptosis Pathway in Prostate Cancer Cells |
| - | in-vivo, | Pca, | RM-1 | - | in-vivo, | Pca, | DU145 |
| 118- | CUR, | Curcumin analog WZ35 induced cell death via ROS-dependent ER stress and G2/M cell cycle arrest in human prostate cancer cells |
| - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | DU145 |
| 134- | CUR, | RES, | MLT, | SIL, | Thioredoxin 1 modulates apoptosis induced by bioactive compounds in prostate cancer cells |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | PC3 |
| 167- | CUR, | Curcumin-induced apoptosis in PC3 prostate carcinoma cells is caspase-independent and involves cellular ceramide accumulation and damage to mitochondria |
| - | in-vitro, | Pca, | PC3 |
| 1982- | CUR, | Inhibition of thioredoxin reductase by curcumin analogs |
| - | in-vitro, | Var, | NA |
| 1981- | CUR, | Mitochondrial targeted curcumin exhibits anticancer effects through disruption of mitochondrial redox and modulation of TrxR2 activity |
| - | in-vitro, | Lung, | NA |
| 1977- | CUR, | Synthesis and evaluation of curcumin analogues as potential thioredoxin reductase inhibitors |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Lung, | A549 |
| 1409- | CUR, | Curcumin analog WZ26 induces ROS and cell death via inhibition of STAT3 in cholangiocarcinoma |
| - | in-vivo, | CCA, | Walker256 |
| 6408- | CUR, | Protective Effects of a Natural Product, Curcumin, against Amyloid β Induced Mitochondrial and Synaptic Toxicities in Alzheimer'S Disease |
| - | in-vitro, | AD, | SH-SY5Y |
| 6213- | CUR, | Potentiality of Curcumin Against Radio-Chemotherapy Induced Oral Mucositis: A Review |
| - | Review, | Var, | NA |
| 6214- | CUR, | Curcumin Nanoparticles-related Non-invasive Tumor Therapy, and Cardiotoxicity Relieve |
| - | Review, | CardioV, | NA |
| 6225- | CUR, | Natural products for enhancing the sensitivity or decreasing the adverse effects of anticancer drugs through regulating the redox balance |
| - | Review, | Var, | NA |
| 6221- | CUR, | Oxidative Stress and Cancer: Harnessing the Therapeutic Potential of Curcumin and Analogues Against Cancer |
| - | Review, | Var, | NA |
| 6209- | CUR, | Curcumin as a complementary treatment in oncological therapy: a systematic review |
| - | Review, | Var, | NA |
| 2812- | CUR, | Curcumin Induces High Levels of Topoisomerase I− and II−DNA Complexes in K562 Leukemia Cells |
| - | in-vitro, | AML, | K562 |
| 2808- | CUR, | Iron chelation by curcumin suppresses both curcumin-induced autophagy and cell death together with iron overload neoplastic transformation |
| - | in-vitro, | Liver, | HUH7 |
| 2978- | CUR, | N-acetyl cysteine mitigates curcumin-mediated telomerase inhibition through rescuing of Sp1 reduction in A549 cells |
| - | in-vitro, | Lung, | A549 |
| 6238- | CUSP9, | A phase Ib/IIa trial of 9 repurposed drugs combined with temozolomide for the treatment of recurrent glioblastoma: CUSP9v3 |
| - | Trial, | GBM, | NA |
| 6236- | CUSP9, | EP, | Tumor Treating Fields (TTFields) combined with the drug repurposing approach CUSP9v3 induce metabolic reprogramming and synergistic anti-glioblastoma activity in vitro |
| - | in-vitro, | GBM, | U251 |
| 6239- | CUSP9, | The efficacy of a coordinated pharmacological blockade in glioblastoma stem cells with nine repurposed drugs using the CUSP9 strategy |
| - | in-vitro, | GBM, | NA |
| 6241- | CUSP9, | RECURRENT GLIOBLASTOMA: INITIAL EXPERIENCES WITH COMPASSIONATE-USE CUSP9v3/v4 |
| - | Trial, | GBM, | NA |
| 9110- | CV, | Antiproliferative effects of carotenoids extracted from Chlorella ellipsoidea and Chlorella vulgaris on human colon cancer cells |
| - | in-vitro, | CRC, | HCT116 |
| 6245- | Cyc, | Blockade of Hedgehog Signaling Inhibits Pancreatic Cancer Invasion and Metastases: A New Paradigm for Combination Therapy in Solid Cancers |
| - | vitro+vivo, | PC, | NA |
| 6252- | Cyc, | Hedgehog Pathway Inhibitors as Targeted Cancer Therapy and Strategies to Overcome Drug Resistance |
| - | Review, | Var, | NA |
| 7442- | CYN, | Cynaropicrin induces the apoptosis of colorectal cancer cells by elevating reactive oxygen species and activating the JNK/p38 MAPK |
| - | in-vitro, | CRC, | HCT116 |
| 7449- | CYN, | Cytotoxic and pro-apoptotic activities of cynaropicrin, a sesquiterpene lactone, on the viability of leukocyte cancer cell lines |
| - | in-vitro, | lymphoma, | U937 | - | in-vitro, | AML, | Jurkat |
| 7444- | CYN, | The Sesquiterpene Lactone Cynaropicrin Manifests Strong Cytotoxicity in Glioblastoma Cells U-87 MG by Induction of Oxidative Stress |
| - | in-vitro, | GBM, | U87MG |
| 7439- | CYN, | Cynaropicrin Induces Reactive Oxygen Species-Dependent Paraptosis-Like Cell Death in Human Liver Cancer Cells |
| - | in-vitro, | Liver, | Hep3B |
| 7438- | CYN, | Cynaropicrin Suppresses Cell Proliferation by Inducing Mitophagy through p38 MAPK-Mediated Mitochondrial ROS Generation in Human Hepatocellular Carcinoma Cells |
| - | in-vitro, | HCC, | NA |
| 6264- | Cyste, | Different inhibition characteristics of intracellular transglutaminase activity by cystamine and cysteamine |
| - | Review, | Nor, | NA |
| 6262- | Cyste, | A Randomized Controlled Crossover Trial with Delayed-Release Cysteamine Bitartrate in Nephropathic Cystinosis: Effectiveness on White Blood Cell Cystine Levels and Comparison of Safety |
| - | Trial, | Nor, | NA |
| 6261- | Cyste, | A comparison of immediate release and delayed release cysteamine in 17 patients with nephropathic cystinosis |
| - | Study, | Var, | NA |
| 6684- | DAP, | GB, | Pharmacological synergism of 2,2-dichloroacetophenone and EGFR-TKi to overcome TKi-induced resistance in NSCLC cells |
| - | vitro+vivo, | NSCLC, | H1975 |
| 1871- | DAP, | Targeting PDK1 with dichloroacetophenone to inhibit acute myeloid leukemia (AML) cell growth |
| - | in-vitro, | AML, | U937 | - | in-vivo, | AML, | NA |
| 6591- | DAS, | Dasatinib in solid tumors |
| - | Review, | Var, | NA |
| 6683- | DCA, | Dichloroacetate for Cancer Treatment: Some Facts and Many Doubts |
| - | Review, | Var, | NA |
| 6682- | DCA, | QC, | Dichloroacetate and Quercetin Prevent Cell Proliferation, Induce Cell Death and Slow Tumor Growth in a Mouse Model of HPV-Positive Head and Neck Cancer |
| - | in-vivo, | HNSCC, | MEER |
| 6681- | DCA, | Dichloroacetate (DCA) in Cancer Care |
| - | Review, | Var, | NA |
| 6679- | DCA, | GSTZ1 genotypes correlate with dichloroacetate pharmacokinetics and chronic side effects in multiple myeloma patients in a pilot phase 2 clinical trial |
| - | Trial, | Melanoma, | NA |
| 1887- | DCA, | GSTZ1 expression and chloride concentrations modulate sensitivity of cancer cells to dichloroacetate |
| - | in-vitro, | Var, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:961 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid